Randomized Placebo-Controlled Trial to Determine the Biological Signature of Cannabidiol as a Treatment for Social Anxiety Disorder

The purpose of this research study is to determine whether cannabidiol (CBD), a non-psychoactive part of cannabis, is an effective treatment for social anxiety disorder (SAD), and to better understand how CBD might improve SAD symptoms. After medical and psychiatric evaluations are completed, eligible participants are randomly assigned (that is, by chance) to one of two treatments lasting approximately 3 weeks: CBD or placebo.

The study will last about 1-2 months and full participation includes 6 study visits as well as fMRI neuroimaging scans, a public speaking exercise, and blood tests. Eligible participants receive compensation for time completing study assessments. 

To see if you’re eligible for this study, please fill out the following pre-screen survey: https://openredcap.nyumc.org/apps/redcap/surveys/?s=CDWKR4K8DXLKF3TN   

NYU Langone Health
Principal Investigator
Naomi Simon 
Eligibility Criteria

Key Eligibility Criteria: Right-handed adults ages 18-45 who have social anxiety disorder 

Study End Date